company background image
UMED

Unité de Fabrication des Médicaments BVMT:UMED Stock Report

Last Price

د.ت7.25

Market Cap

د.ت232.0m

7D

1.3%

1Y

-7.4%

Updated

06 Dec, 2022

Data

Company Financials +
UMED fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance1/6
Financial Health4/6
Dividends1/6

UMED Stock Overview

Unité de Fabrication des Médicaments S.A.

Unité de Fabrication des Médicaments S.A Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Unité de Fabrication des Médicaments
Historical stock prices
Current Share Priceد.ت7.25
52 Week Highد.ت8.10
52 Week Lowد.ت6.77
Beta0.070
1 Month Change-1.36%
3 Month Change-7.99%
1 Year Change-7.41%
3 Year Change-22.63%
5 Year Change-2.95%
Change since IPO-30.36%

Recent News & Updates

Recent updates

Shareholder Returns

UMEDTN PharmaceuticalsTN Market
7D1.3%-0.4%-0.5%
1Y-7.4%-24.8%0.3%

Return vs Industry: UMED exceeded the TN Pharmaceuticals industry which returned -24.8% over the past year.

Return vs Market: UMED underperformed the TN Market which returned 0.3% over the past year.

Price Volatility

Is UMED's price volatile compared to industry and market?
UMED volatility
UMED Average Weekly Movement3.1%
Pharmaceuticals Industry Average Movement4.4%
Market Average Movement3.0%
10% most volatile stocks in TN Market5.2%
10% least volatile stocks in TN Market1.8%

Stable Share Price: UMED is not significantly more volatile than the rest of TN stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: UMED's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1989n/aRidha Charfeddinehttps://www.unimed.com.tn

Unité de Fabrication des Médicaments S.A. develops, manufactures, markets, and sells generic medicines under the UNIMED brand in Tunisia, Africa, Asia, and Europe. The company’s products include ophta-ORL solutions, liquids for injections, penicillin powders, cephalosporins for injections, inhalations, and perfusion solutions, as well as vaigtaine products in approximately 40 presentations for various therapeutic classes. It also manufactures medicines for third party laboratories.

Unité de Fabrication des Médicaments S.A Fundamentals Summary

How do Unité de Fabrication des Médicaments's earnings and revenue compare to its market cap?
UMED fundamental statistics
Market Capد.ت232.00m
Earnings (TTM)د.ت5.08m
Revenue (TTM)د.ت86.32m

45.7x

P/E Ratio

2.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
UMED income statement (TTM)
Revenueد.ت86.32m
Cost of Revenueد.ت40.77m
Gross Profitد.ت45.55m
Other Expensesد.ت40.47m
Earningsد.ت5.08m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.16
Gross Margin52.76%
Net Profit Margin5.88%
Debt/Equity Ratio43.0%

How did UMED perform over the long term?

See historical performance and comparison

Dividends

5.6%

Current Dividend Yield

256%

Payout Ratio